Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Teva
Deloitte
Medtronic
QuintilesIMS
Citi
US Department of Justice
Baxter
Fuji
Dow

Generated: August 23, 2017

DrugPatentWatch Database Preview

Teriflunomide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for teriflunomide and what is the scope of teriflunomide patent protection?

Teriflunomide
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Teriflunomide has fifty-six patent family members in thirty-seven countries.

There are eighteen drug master file entries for teriflunomide. One supplier is listed for this compound.

Summary for Generic Name: teriflunomide

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list18
Suppliers / Packagers: see list1
Bulk Api Vendors: see list53
Clinical Trials: see list28
Patent Applications: see list1,070
Drug Prices:see low prices
DailyMed Link:teriflunomide at DailyMed

Pharmacology for Ingredient: teriflunomide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-001Sep 12, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-001Sep 12, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-002Sep 12, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-002Sep 12, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-002Sep 12, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: teriflunomide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-002Sep 12, 2012► Subscribe► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-001Sep 12, 2012► Subscribe► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-002Sep 12, 2012► Subscribe► Subscribe
Sanofi Aventis Us
AUBAGIO
teriflunomide
TABLET;ORAL202992-001Sep 12, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: teriflunomide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,569,898 United States Patent: 6569898   ( 1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: teriflunomide

Country Document Number Estimated Expiration
Uruguay32889► Subscribe
Canada2772275► Subscribe
TaiwanI468190► Subscribe
Israel244809► Subscribe
European Patent Office2762135► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TERIFLUNOMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00005Denmark► SubscribePRODUCT NAME: TERIFLUNOMID, DETS STEREOISOMER OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/13/838/001-005 20130826
00644Netherlands► SubscribePRODUCT NAME: TERIFLUONOMIDE, ITS STEROISOMER AND PHARAMCEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
2014004Lithuania► SubscribePRODUCT NAME: TERIFLUNOMIDUM; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
6Finland► Subscribe
14/004Ireland► SubscribePRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Harvard Business School
Chinese Patent Office
Fuji
Novartis
Daiichi Sankyo
Federal Trade Commission
Cantor Fitzgerald
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot